Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Haploinsufficiency of mechanistic target of rapamycin ameliorates bag3 cardiomyopathy in adult zebrafish
Ding, Yonghe , Dvornikov, Alexey V. , Ma, Xiao , Wang, Yong , Lowerison, Matthew R. , Packard, René R. Sevag , Wang, Lei , Zhang, Yuji , Lowerison, Matthew, Lin, Xueying , Lowerison, Matthew , Ding, Yonghe , Zhang, Hong , Chen, Jun , Hsiai, Tzung K. , Xu, Xiaolei , Packard, Rene R S

Mayo Clinic

Disease Models & Mechanisms | September 6, 2019 | Volume: 12 | Issue: 10 | Pages: No page available

10.1242/dmm.040154 | PMID 31492659 Get It

ABSTRACT The adult zebrafish is an emerging vertebrate model for studying human cardiomyopathies; however, whether the simple zebrafish heart can model different subtypes of cardiomyopathies, such as dilated cardiomyopathy (DCM), remains elusive. Here, we generated and characterized an inherited DCM model in adult zebrafish and used this model to search for therapeutic strategies. We employed transcription activator-like effector nuclease (TALEN) genome editing technology to generate frame-shift mutants for the zebrafish ortholog of human BCL2-associated athanogene 3 (BAG3), an established DCM-causative gene. As in mammals, the zebrafish bag3 homozygous mutant (bag3e2/e2) exhibited aberrant proteostasis, as indicated by impaired autophagy flux and elevated ubiquitinated protein aggregation. Through comprehensive phenotyping analysis of the mutant, we identified phenotypic traits that resembled DCM phenotypes in mammals, including cardiac chamber enlargement, reduced ejection fraction characterized by increased end-systolic volume/body weight (ESV/BW), and reduced contractile myofibril activation kinetics. Nonbiased transcriptome analysis identified the hyperactivation of the mechanistic target of rapamycin (mTOR) signaling in bag3e2/e2 mutant hearts. Further genetic studies showed that mtorxu015/+, an mTOR haploinsufficiency mutant, repaired abnormal proteostasis, improved cardiac function and rescued the survival of the bag3e2/e2 mutant. This study established the bag3e2/e2 mutant as a DCM model in adult zebrafish and suggested mtor as a candidate therapeutic target gene for BAG3 cardiomyopathy.
POD24 in MZL: a means to an end or an end point in itself?
Maurer, Matthew J. , Maurer, Matthew

Mayo Clinic

Blood | September 5, 2019 | Volume: 134 | Issue: 10 | Pages: 787-788

10.1182/blood.2019002305 | PMID 31488454 Get It

Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration
Bejanin, Alexandre , Murray, Melissa E. , Martin, Peter R. , Botha, Hugo , Tosakulwong, Nirubol , Senjem, Matthew L. , Chételat, Gaël , Kantarci, Kejal , Jack, Clifford R. , Knopman, David S. , Petersen, Ronald , Parisi, Joseph E., Whitwell, Jennifer L. , Josephs, Keith A. , Jack, Clifford R , Senjem, Matthew L , Bejanin, Alexandre , Kantarci, Kejal , Botha, Hugo , Murray, Melissa E , Schwarz, Christopher G. , Boeve, Bradley F. , Knopman, David S. , Giannini, Caterina , Dickson, Dennis W.

Mayo Clinic

Brain | September 4, 2019 | Volume: 142 | Issue: 11 | Pages: 3621-3635

10.1093/brain/awz277 | PMID 31562527 Get It

The specific effect of TDP-43 pathology on grey matter volume in individuals without frontotemporal lobar degeneration is unclear. Bejanin et al. reveal a major and independent contribution of TDP-43 to neurodegeneration and shed light on the regional distribution of TDP-43-related atrophy in older adults.
Return to Duty After Mini‐Open Arthroscopic‐Assisted Treatment of Femoroacetabular Impingement in an Active Military Population
Song, Daniel J. , Lee, Gregory Y., Tokish, John M. , Ernat, Justin J. , Cage, J. Matthew

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | September 4, 2019 | Volume: 1 | Issue: 1 | Pages: No page available

10.1016/j.asmr.2019.07.003 | PMID 32267252 Get It

Purpose To report the return‐to‐duty rate and surgical outcomes in a military population after mini‐open arthroscopic‐assisted surgery for femoroacetabular impingement (FAI) in an effort to affirm its efficacy. Methods A retrospective review of consecutive active‐duty patients receiving mini‐open arthroscopic‐assisted surgery for FAI between 2007 and 2011 was performed. Patients younger than 18 years, non–active‐duty patients, and patients with prior hip surgery were excluded. Demographic, radiographic, and duty‐status data were collected. The primary outcome measure was a return to duty. Outcome scores were obtained in a proportion of the cohort, including the modified Harris Hip Score, Single Assessment Numeric Evaluation score, Western Ontario and McMaster Universities Osteoarthritis Index score, patient satisfaction score, and Veterans RAND 12 (VR‐12) score. All patients had achieved a minimum of 1 year of follow‐up at the time of assessment. All P values for significance were set at .05 or lower. Results Of 182 patients (average age, 30.4 years), 156 (86%) were available for follow‐up with return‐to‐duty data at an average of 2.8 years (range, 1‐6 years). Of the patients, 78% returned to full duty (53%) or returned to duty with restrictions (25%). Outcome scores were available for 101 of 182 patients (55%) with duty rates similar to the total cohort (81% who returned to duty: 58% with no restrictions and 23% with restrictions). Return to duty correlated with improved outcomes compared with those who were medically discharged with respect to the modified Harris Hip Score (68.2 vs 54.5, P < .03), Single Assessment Numeric Evaluation score (48.2 vs 25.3, P < .02), and VR‐12 physical (39.7 vs 33.2, P < .05) and VR‐12 mental (54.5 vs 43.4, P < .005) scores. Conclusions Mini‐open arthroscopic‐assisted surgery for FAI is successful in returning most service members to duty at short‐term follow‐up. Return correlates with improved outcome scores, although previously reported minimally clinical important difference and patient acceptable symptomatic state threshold values were not uniformly achieved. Level of Evidence Level IV, retrospective case series.
Impact of Chronic Obstructive Pulmonary Disease on Postoperative Complications Following Simultaneous Bilateral Total Knee Arthroplasty
Gu, Alex , Wu, Shitong, Mancino, Fabio , Liu, Jiabin , Ast, Michael P. , Abdel, Matthew P. , Sculco, Peter K.

Mayo Clinic

The Journal of Knee Surgery | August 30, 2019 | Volume: 34 | Issue: 03 | Pages: 322-327

10.1055/s-0039-1695766 | PMID 31470451 Get It

AbstractFor patients who qualify, simultaneous bilateral total knee arthroplasty (TKA) is a viable option for the treatment of bilateral symptoms. However, the incidence of chronic obstructive pulmonary disease (COPD) has been steadily rising over the past few decades and may impact those who qualify as candidates for bilateral TKA. As such, the aim of this study was to determine the impact of COPD on postoperative outcomes in patients who receive simultaneous bilateral TKA. A retrospective cohort study was conducted utilizing data provided through the American College of Surgeons National Surgical Quality Improvement Program. All patients who had undergone simultaneous bilateral TKA between 2007 and 2016 were identified and further stratified into groups based upon the COPD status. Incidence of adverse events after TKA in the acute postoperative period was evaluated with univariate and multivariate analyses. COPD was found to be an independent risk factor for the development of major (odds ratio [OR]: 2.5; p = 0.015), renal (OR: 5.1; p = 0.02), and thromboembolic complications (OR: 2.5; p = 0.027). In addition, patients with COPD were at increased risk for having an extended hospital length of stay (LOS; p < 0.001) and development of urinary tract infections (p < 0.001). Patients with COPD are at higher risk for development of overall major complications, as well as renal and thromboembolic complications after simultaneous bilateral TKA. Interestingly, patients were not at increased risk for the development of pulmonary or wound complications. When considering a staged versus simultaneous bilateral TKA, surgeons should be aware of the impact COPD status has on the postoperative complication rate.
Involvement of the Cochlear Aqueduct by Jugular Paraganglioma Is Associated With Sensorineural Hearing Loss
Patel, Neil , Link, Michael J. , Driscoll, Colin L. W., Neff, Brian A., Lane, John I. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | August 30, 2019 | Volume: 40 | Issue: 9 | Pages: 1230-1236

10.1097/mao.0000000000002346 | PMID 31469795 Get It

Objective: The etiology of sensorineural hearing loss (SNHL) in patients with jugular paraganglioma (JP) whose tumors lack inner ear fistulae or vestibulocochlear nerve involvement is unknown. Recent literature has proposed that occlusion of the inferior cochlear vein may be causative. Herein, we assess the association between radiologic involvement of the cochlear aqueduct (CA) and the development of SNHL. Study Design: Blinded, retrospective review of imaging and audiometry. Setting: Tertiary center. Patients: Adults with JP. Intervention(s): None. Main Outcome Measures: Asymmetric SNHL was assessed continuously as the difference in bone conduction pure-tone average (BCPTA) between ears and as a categorical variable (≥15 dB difference at two consecutive frequencies, or a difference in speech discrimination score of ≥15%). Involvement of the CA was considered present if there was evidence of medial T2 fluid signal loss, contrast enhancement, or bony erosion/expansion. Results: Of 30 patients meeting inclusion criteria, 15 (50%) had asymmetric SNHL. CA involvement was observed in 87% of patients with asymmetric SNHL compared with 13% in those with symmetric hearing (p = 0.0001). Univariate analysis demonstrated that age, sex, and tumor volume were not associated with asymmetric SNHL. The median difference in BCPTA between ears in patients with CA involvement was 21.3 dB HL compared to 1.2 dB HL in those without CA involvement (p < 0.0001). Regression analysis demonstrates that enhancement within the CA is associated with a BCPTA difference of 19.4 dB HL (p = 0.0006). Conclusions: Cochlear aqueduct involvement by JP is associated with SNHL in the absence of inner ear fistula, vestibulocochlear nerve involvement, or brainstem compression. Correlation with operative findings or histopathologic evidence of tumor involvement may validate this intriguing imaging finding.
Delayed Tumor Growth in Vestibular Schwannoma: An Argument for Lifelong Surveillance
Macielak, Robert J. , Patel, Neil , Lees, Katherine A. , Lohse, Christine M. , Marinelli, John P. , Link, Michael J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | August 30, 2019 | Volume: 40 | Issue: 9 | Pages: 1224-1229

10.1097/mao.0000000000002337 | PMID 31469794 Get It

Objective: Previous research has shown that tumor growth during observation of small-to-medium sized sporadic vestibular schwannomas (VSs) occurs almost exclusively within 3 to 5 years following diagnosis. This has led some to consider ending surveillance after this interval. This study seeks to characterize a cohort of patients with tumors that exhibited late growth. Study Design: Retrospective cohort study. Setting: Tertiary referral center. Patients: Adults with sporadic VSs who initially elected observation with serial magnetic resonance imaging (MRI) surveillance. Intervention(s): None. Main Outcome Measure(s): Linear tumor growth was measured in accordance with AAO-HNS reporting guidelines. Delayed growth was defined as growth ≥2 mm in linear diameter that was first detected 5 years or more from the initial MRI. Results: From a total of 361 patients, 172 experienced tumor growth during the interval of observation. Fourteen of these 172 patients (8.1%) experienced late growth occurring at 5 years or beyond. Among patients with delayed growth, the fastest growth rate after extended quiescence was 1.33 mm/yr, and the longest delay before tumor growth detection was 11.1 years. Additional treatment was recommended for six (42.9%) of the patients with delayed growth. Of 68 tumors that remained in the IAC, 11 (16.2%) demonstrated delayed growth. Of 66 tumors that presented in the CPA, 2 (3.0%) demonstrated delayed growth. Initial size was larger for tumors demonstrating early growth compared with those with delayed growth. For tumors within the IAC, those with early growth had a significantly higher median growth rate than those with delayed growth (1.40 vs. 0.45 mm/yr, p < 0.001). Conclusions: Delayed growth encompassed 8.1% of growing VSs and 3.9% of all observed tumors. Patients with delayed growth exhibited slower growth rates compared with those who were diagnosed with growth early in their observation course. These findings support the need for lifelong surveillance of untreated VSs given the possibility of clinically significant delayed growth. Increasing the time interval between MRI studies after 5 years is a reasonable concession to balance practicalities of cost and convenience with risk of delayed of tumor growth.
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Jack, Clifford R. , Wiste, Heather J. , Botha, Hugo , Weigand, Stephen D. , Therneau, Terry M. , Graff‐Radford, Jonathan , Ferman, Tanis J. , Boeve, Bradley F. , Kantarci, Kejal , Lowe, Val J. , Vemuri, Prashanthi , Fields, Julie A. , Senjem, Matthew L. , Gunter, Jeffrey L. , Petersen, Ronald C. , Jack, Clifford R , Boeve, Brad , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Botha, Hugo , Ferman, Tanis J , Knopman, David S. , Jones, David T. , Mielke, Michelle M. , Machulda, Mary M. , Schwarz, Christopher G.

Mayo Clinic

Brain | August 28, 2019 | Volume: 142 | Issue: 10 | Pages: 3230-3242

10.1093/brain/awz268 | PMID 31501889 Get It

See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.
The fifth vital sign? Nurse worry predicts inpatient deterioration within 24 hours
Gaines, Kim, Nicolas, Clara T., Johnson, Matthew G. , Hickman, Joel , Romero-Brufau, Santiago, Romero‐Brufau, Santiago , Huddleston, Jeanne M.

Mayo Clinic

JAMIA Open | August 28, 2019 | Volume: 2 | Issue: 4 | Pages: 465-470

10.1093/jamiaopen/ooz033 | PMID 32025643 Get It

Abstract Introduction Identification of hospitalized patients with suddenly unfavorable clinical course remains challenging. Models using objective data elements from the electronic health record may miss important sources of information available to nurses. Methods We recorded nurses’ perception of patient potential for deterioration in 2 medical and 2 surgical adult hospital units using a 5-point score at the start of the shift (the Worry Factor [WF]), and any time a change or an increase was noted by the nurse. Cases were evaluated by three reviewers. Intensive care unit (ICU) transfers were also tracked. Results 31 159 patient-shifts were recorded for 3185 unique patients during 3551 hospitalizations, with 169 total outcome events. Out of 492 potential deterioration events identified, 380 (77%) were confirmed by reviewers as true deterioration events. Likelihood ratios for ICU transfer were 17.8 (15.2–20.9) in the 24 hours following a WF &gt; 2, and 40.4 (27.1–60.1) following a WF &gt; 3. Accuracy rates were significantly higher in nurses with over a year of experience (68% vs 79%, P = 0.04). The area under the receiver operator characteristic curve (AUROC) was 0.92 for the prediction of ICU transfer within 24 hours. Discussion This is a higher accuracy than most published early warning scores. Conclusion Nurses’ pattern recognition and sense of worry can provide important information for the detection of acute physiological deterioration and should be included in the electronic medical record.